A surge of research highlights the therapeutic potential of psychedelics like psilocybin and MDMA in treating conditions such as depression and PTSD. With breakthrough therapy designations from the FDA, studies show that supportive psychotherapy combined with these substances can lead to significant symptom reduction, particularly among those with treatment-resistant conditions. Remarkably, a year after treatment, many patients no longer meet the criteria for PTSD, showcasing a promising future for psychedelic-assisted therapy.
